Capricor Therapeutics shares are trading lower by 2.7% during Thursday's session. The company earlier commenced its public offering of common stock. Henry Khederian CSX Posts Weak Earnings, Joins ...

Capricor Therapeutics (CAPR) is expected to deliver a year-over ... how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in ...

Capricor Therapeutics (CAPR) closed the last trading session at $18.09, gaining 330.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

Capricor Therapeutics (NASDAQ:CAPR) stock rose 5% in midday trading Friday after the company reported positive long-term data from a study of its drug deramiocel in the treatment of Duchenne ...

The company earlier commenced its public offering of common stock. Capricor Therapeutics Inc CAPR shares are trading lower by 6.05% to $19.27 during Thursday’s session. The company earlier ...

Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor’s ...

There are several stocks that passed through the screen and (CAPR) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing. A solid price increase over a ...

There are several stocks that passed through the screen and (CAPR) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing. A solid price increase over a ...